U.S. Senate Advances SBIR/STTR Reauthorization, Restoring a Critical Innovation Pipeline

After months of uncertainty for startups and technology innovators across the country, the U.S. Senate has passed bipartisan legislation, S. 9371, to reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs - two of the federal government’s most important funding mechanisms for early-stage technology development. 

The compromise legislation would extend the programs through September 30, 2031, restoring stability to a funding pipeline that lapsed after the previous authorization expired in September 2025. For Michigan’s growing life sciences ecosystem, the Senate’s action represents an important step toward ensuring continued access to non-dilutive capital that helps companies advance new therapeutics, diagnostics, medical devices, and health technologies. 

While the bill still must complete the legislative process, the Senate vote signals strong bipartisan support for maintaining federal investment in small-business innovation. 

Why SBIR/STTR Matter 

For more than four decades, SBIR and STTR have served as the federal government’s primary vehicle for funding innovation in small businesses. The programs provide competitive research and development awards to startups and small companies developing technologies with strong commercialization potential. 

Across agencies such as the National Institutes of Health (NIH), the Department of Defense (DoD), and the National Science Foundation (NSF), the programs collectively distribute billions of dollars annually in innovation funding. 

Awards are typically structured in phases: 

• Phase I supports early feasibility and proof-of-concept research. 

• Phase II provides larger awards to advance development and validation. 

• Phase III focuses on commercialization through private investment or federal procurement. 

For life science companies - where development timelines are long and capital requirements are significant - SBIR and STTR awards often provide critical early funding that helps bridge the gap between academic research and venture investment. 

Key Elements of the Senate Legislation 

The Senate compromise includes several provisions intended to strengthen the programs while addressing concerns raised during the reauthorization debate. 

 Key elements include: 

• Extension of SBIR/STTR through 2031, providing greater certainty for startups and federal agencies. 

• Enhanced national security and foreign risk screening to safeguard sensitive technologies supported through federal funding. 

• Creation of a “Strategic Breakthrough Award” pathway, allowing agencies to issue larger follow-on awards - potentially up to $30 million - for high-impact technologies after Phase II. 

• Proposal submission limits aimed at reducing excessive proposal volume from a small number of repeat applicants and broadening participation. 

• Expanded commercialization support, including improved pathways from federally funded R&D to market adoption. 

These reforms are intended to strengthen program oversight while preserving SBIR/STTR’s role as the nation’s leading source of seed-stage funding for technology innovation. 

What Happens Next 

Although Senate passage represents a major step forward, several steps remain before the reauthorization becomes law. 

The legislation must be finalized through the House of Representatives and then signed by the President. The temporary lapse in authorization created uncertainty across the innovation community, and some federal agencies delayed or adjusted solicitations while awaiting congressional action. 

Once the reauthorization is completed, agencies are expected to resume regular SBIR/STTR funding cycles and release new solicitations under the updated framework. Companies developing biomedical technologies, medical devices, and other advanced innovations will likely see renewed opportunities through agencies such as NIH, NSF, and DoD. 

Implications for Michigan’s Life Sciences Sector 

Michigan’s life sciences companies - many emerging from the state’s research universities and health systems - have long leveraged SBIR and STTR funding to advance new technologies. 

For early-stage ventures developing therapeutics, diagnostics, and medical technologies, the programs provide several key advantages: 

• Access to non-dilutive capital - SBIR/STTR awards allow startups to advance early technical milestones without giving up equity, helping founders maintain ownership while strengthening their technologies. 

• A pathway from research to commercialization - For many university spinouts, these awards represent the first major investment supporting the transition from academic discovery to commercial development. 

• Potential for larger follow-on funding - The proposed Strategic Breakthrough Award pathway could provide significantly larger funding opportunities for technologies with national or strategic importance, including biomedical innovation. 

• Greater opportunity for emerging innovation regions - Federal policymakers have emphasized expanding participation beyond traditional coastal innovation hubs, potentially creating new opportunities for Midwest ecosystems like Michigan. 

For Michigan’s life sciences ecosystem, these programs remain a critical component of the state’s innovation pipeline - providing early-stage funding that helps companies generate the data needed to attract private investment, form partnerships, and ultimately bring new health technologies to market. 

MichBio is actively continuing its advocacy efforts in the U.S. House to ensure timely passage of the legislation in short order - we just came back from a Capitol Hill visit, and plan to be there again late March and mid-April during scheduled Fly-ins.